Pacific Biosciences of California, Inc. Q3 2026 Earnings Recap

PacBio shares fell 4.7% after earnings, as higher revenue and instrument placements were tempered by a still-modest consumables increase and management’s acknowledgement of uneven capital purchasing, particularly in the Americas. The SPRQ-Nx transition is progressing, but customers are still validating workflows and establishing reorder patterns, leaving the timing of higher utilization uncertain.

Key Takeaways

• Q3 revenue was $40.6 million, up from $38.4 million a year earlier and $39 million in Q2.
• Consumables revenue rose to $20.8 million from $20.1 million sequentially; Revio pull-through was approximately $204,000, and management maintained its full-year range of $200,000–$225,000 per system.
• SPRQ-Nx accounted for over half of Revio consumable revenue, and two-thirds of the Revio installed base had opted into the software upgrade by quarter-end. Management said customers are still validating multi-use workflows and working through inventory.
• Instrument revenue increased 17% year over year to $13.2 million. PacBio placed 15 Revio systems and 35 Vega systems; Vega placements were up 35% sequentially.
• Management cited uneven capital purchasing, especially in the Americas, and expects more SPRQ-Nx reorders in coming months, with higher pull-through anticipated in 2027 and beyond.